<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Obstetric anesthesia for patients with opioid use disorder or opioid tolerance</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Obstetric anesthesia for patients with opioid use disorder or opioid tolerance</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Obstetric anesthesia for patients with opioid use disorder or opioid tolerance</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sharon Reale, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michaela K Farber, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David L Hepner, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marianna Crowley, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 28, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3712737727"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Opioid use during pregnancy has increased in parallel with the opioid epidemic. Providing peripartum analgesia and anesthesia may be uniquely challenging in patients who use opioids or who have opioid use disorder (OUD) due to opioid tolerance, opioid induced hyperalgesia, and the potential for withdrawal. This topic will discuss anesthesia and analgesia for labor and delivery in patients with OUD or opioid tolerance. </p><p>The management of OUD during pregnancy is discussed separately. </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4799.html" rel="external">"Substance use during pregnancy: Screening and prenatal care"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4790.html" rel="external">"Opioid use disorder: Overview of treatment during pregnancy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/87238.html" rel="external">"Opioid use disorder: Pharmacotherapy with methadone and buprenorphine during pregnancy"</a>.)</p><p></p><p class="headingAnchor" id="H3325608151"><span class="h1">ANTENATAL ANESTHESIA CONSULTATION</span><span class="headingEndMark"> — </span>Screening for substance use and misuse is part of routine obstetric care (see  <a class="medical medical_review" href="/z/d/html/4799.html" rel="external">"Substance use during pregnancy: Screening and prenatal care", section on 'Screening for substance use'</a>). Once identified, parturients who chronically use opioids may benefit from antenatal high-risk anesthetic consultation in order to address patient concerns and to create a plan for peripartum analgesia or anesthesia, often in coordination with the clinicians who prescribe opioids or manage OUD [<a href="#rid1">1,2</a>].</p><p>Evaluation of pregnant patients with OUD for concomitant medical and psychosocial disorders is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4790.html" rel="external">"Opioid use disorder: Overview of treatment during pregnancy", section on 'Pretreatment maternal evaluation'</a>.) </p><p>In addition to routine obstetric preanesthesia evaluation, the following areas are of particular focus during the anesthesia consultation for patients with OUD or who are currently prescribed opioids.</p><p class="headingAnchor" id="H724410877"><span class="h2">Current opioid therapy</span><span class="headingEndMark"> — </span>Patients with chronic pain or OUD may be taking prescription opioids, including <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a> or <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> for OUD. The quantity of opioids used daily should be ascertained as accurately as possible, including individual doses, intervals, and total daily dose, and should be reconfirmed at the time of delivery. In general, the patient's baseline medication regimen for OUD, including buprenorphine or methadone, should be continued in the peripartum period in order to prevent maternal or neonatal withdrawal and if applicable, to maintain the existing level of chronic pain control. However, the baseline medication for OUD (MOUD) regimen is not sufficient to treat peripartum pain. (See  <a class="medical medical_review" href="/z/d/html/87238.html" rel="external">"Opioid use disorder: Pharmacotherapy with methadone and buprenorphine during pregnancy", section on 'Intrapartum and postpartum buprenorphine dosing'</a> and  <a class="medical medical_review" href="/z/d/html/87238.html" rel="external">"Opioid use disorder: Pharmacotherapy with methadone and buprenorphine during pregnancy", section on 'Intrapartum and postpartum methadone dosing'</a>.)</p><p>For patients with OUD that is untreated, baseline opioid dose may be impossible to determine, particularly in the setting of illicit opioid use. Management to prevent withdrawal for patients with untreated OUD is discussed below. (See <a class="local">'Continue baseline opioid'</a> below.)</p><p class="headingAnchor" id="H3289607958"><span class="h2">Concomitant medications</span><span class="headingEndMark"> — </span>Up to 35 percent of opioid-dependent pregnant patients report use of additional pain or psychotropic medications [<a href="#rid3">3</a>]. The use of any illicit, psychotropic, or additional pain medication should be determined to anticipate both increased risk of withdrawal during the hospitalization, and a compounded risk of respiratory depression. </p><p>Patients should be asked about nicotine use, which is more common in patients with OUD and may be an independent risk factor for increased postpartum pain after delivery in patients with OUD [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H1954897886"><span class="h2">Concurrent psychiatric conditions or social stressors</span><span class="headingEndMark"> — </span>Coexisting depression and anxiety are common in patients with OUD, and these conditions and potential psychosocial stressors should be identified during the preanesthetic consultation [<a href="#rid4">4,5</a>]. (See  <a class="medical medical_review" href="/z/d/html/99647.html" rel="external">"Opioid use disorder: Psychosocial management"</a> and  <a class="medical medical_review" href="/z/d/html/16753.html" rel="external">"Substance use disorders: Psychosocial management"</a> and  <a class="medical medical_review" href="/z/d/html/14344.html" rel="external">"Treatment of co-occurring anxiety-related disorders and substance use disorders in adults"</a>.)</p><p>Both pre-delivery anxiety and depression and severe acute postdelivery pain are associated with increased risk for chronic pain 3, 6, and 12 months after cesarean delivery [<a href="#rid6">6</a>]. Furthermore, higher intensity of immediate postpartum pain after vaginal or cesarean delivery is predictive of postpartum depression. [<a href="#rid7">7</a>]. Taken together, optimizing pre-delivery anxiety and depression and acute postdelivery pain are important priorities for patients with OUD. Resources including psychology or psychiatry consultation and social support networks may be beneficial and should be explored.</p><p class="headingAnchor" id="H87660954"><span class="h2">Patient concerns</span><span class="headingEndMark"> — </span>During the pre-anesthesia visit, the anesthesia clinician should elicit and address patient concerns, which may include anxiety over and fear of pain, possibility of withdrawal, and the possibility of negative interactions with medical staff. The visit should be empathetic and nonjudgmental, with a focus on building a strong patient-provider relationship, lifting any stigma associated with opioid use, and establishing appropriate expectations for care. The discussion should include the patient's pain tolerance and her expectations for labor analgesia or cesarean delivery.</p><p>It may be helpful to discuss any prior history of withdrawal, and to reassure the patient that preventing withdrawal is a key focus throughout the peripartum period. </p><p class="headingAnchor" id="H1169837690"><span class="h1">CREATING A MANAGEMENT PLAN</span><span class="headingEndMark"> — </span>Effective management of patients who chronically use opioids or with OUD requires an integrated approach that includes the patient, obstetrician, and anesthesiologist, and may include the pain management clinician and psychiatrist or addiction medicine specialist. The goal is to develop a patient-centered individualized plan that is realistic, safe, and attainable, recognizing the variability of analgesic requirements and unpredictability of labor and delivery [<a href="#rid8">8,9</a>]. </p><p>The limited available literature on management of analgesia and anesthesia for labor and delivery for patients with OUD consists of small case series and retrospective reviews which reflect heterogenous management strategies [<a href="#rid4">4,10-16</a>]. Some studies have reported increased need for postpartum analgesia in patients who chronically use opioids, while others have not. Examples include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>In a single institution retrospective case control study of 68 pregnant patients maintained on <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> for OUD (35 after vaginal delivery, 33 after cesarean delivery), peripartum analgesia was compared with controls [<a href="#rid13">13</a>]. Patients on methadone for OUD had similar pain and analgesia during pregnancy, and similar opioid use after vaginal delivery despite reporting increased pain after delivery. After cesarean delivery, patients on methadone had increased postoperative pain (5 versus 3 on a scale of 0 to 10) despite increased opioid use that was in addition to their maintenance methadone dose (92 versus 54 <a class="drug drug_general" data-topicid="9729" href="/z/d/drug information/9729.html" rel="external">oxycodone</a> milligram equivalents/24 hours). Eighty percent of patients in both study groups received neuraxial analgesia. Of note, all cesarean delivery patients received spinal anesthesia, but only 27 and 21 percent received long-acting intrathecal opioid in the OUD and control groups, respectively. Furthermore, no alternate truncal blocks such as a transversus abdominis plane (TAP) were performed in the OUD or control groups. The external validity of these findings may be limited, however, as intrathecal opioids are now rarely withheld and truncal blocks have increased in use. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A separate retrospective case control study from the same institution showed similar results for pregnant patients with OUD on <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a>; 63 patients who delivered while on buprenorphine for OUD (44 vaginal, 19 cesarean) had similar intrapartum pain scores compared with controls [<a href="#rid14">14</a>]. Again, patients maintained on buprenorphine reported more pain following vaginal delivery, without an increase in opioid use; after cesarean delivery, buprenorphine as medication for opioid use disorder (MOUD) was associated with increased pain and a 47 percent increase in opioid use (89 versus 81 <a class="drug drug_general" data-topicid="9729" href="/z/d/drug information/9729.html" rel="external">oxycodone</a> milligram equivalents). Similar to the study above, over 80 percent of all patients received neuraxial labor analgesia, but very few patients received long-acting intrathecal opioids for cesarean delivery.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A retrospective analysis of data collected as part of the Maternal Opioid Treatment: Human Experimental Research trial analyzed data for 37 patients receiving treatment for OUD with <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a> versus <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a>, compared with patients who were not opioid dependent [<a href="#rid4">4</a>]. Pain and analgesic use after vaginal delivery were similar between groups; patients on MOUD received more nonsteroidal antiinflammatory drugs (NSAIDs) but fewer opioids after cesarean delivery than patients who were not opioid dependent. Patients on MOUD requested epidural labor analgesia more often (38.1 versus 14.3 percent), though generalizability is uncertain due to the low epidural utilization rate in both groups. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a single institution retrospective review of 2979 patients who underwent cesarean delivery, 123 of whom were taking <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a> or <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> for treatment of OUD, patients who were taking MOUD consumed more additional opioids (median total 99 versus 30 milligram <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a> equivalents) and had higher peak pain scores (8.2 versus 5.5/10) in the first 24 hours after surgery [<a href="#rid17">17</a>]. Outcomes were similar in patients who were taking buprenorphine versus methadone. </p><p></p><p class="headingAnchor" id="H3402311323"><span class="h1">GENERAL PRINCIPLES</span><span class="headingEndMark"> — </span>General principles of management for obstetric patients who chronically use opioids are similar to those that apply to nonpregnant patients who chronically use opioids. For most patients, baseline opioid should be continued. Neuraxial anesthesia techniques are preferred for both labor analgesia and operative delivery, supplemented with multimodal nonopioid analgesics, and additional opioids added as necessary. Overarching goals are to provide adequate analgesia, and to avoid withdrawal, oversedation, and respiratory depression  (<a class="graphic graphic_table graphicRef132055" href="/z/d/graphic/132055.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/83726.html" rel="external">"Management of acute pain in the patient chronically using opioids for non-cancer pain", section on 'Treatment goals'</a>.) </p><p class="headingAnchor" id="H1952818967"><span class="h2">Continue baseline opioid</span><span class="headingEndMark"> — </span>For all patients who chronically use opioids or who have OUD, baseline opioid therapy should be continued throughout the peripartum period to prevent withdrawal and to maintain the antepartum level of analgesia, if applicable. For patients who are unable to swallow or absorb oral medications, an oral dose can be converted to a parenteral equivalent  (<a class="graphic graphic_table graphicRef111216" href="/z/d/graphic/111216.html" rel="external">table 2</a>). Important safeguards and details regarding opioid conversion are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2814.html" rel="external">"Cancer pain management with opioids: Optimizing analgesia", section on 'Equianalgesic opioid dose conversion'</a>.)</p><p>While it was previously recommended that medication for opioid use disorder (MOUD) be stopped prior to surgery or other episodes associated with acute pain, this is no longer recommended. Discontinuation may precipitate a relapse in the peripartum period, and can expose the patient and the newborn to potential risks of withdrawal. (See  <a class="medical medical_review" href="/z/d/html/87238.html" rel="external">"Opioid use disorder: Pharmacotherapy with methadone and buprenorphine during pregnancy"</a>.)</p><p>For patients on MOUD admitted for labor and delivery, we typically continue the patient’s prescribed MOUD dose; while <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> dosing is typically once daily, a more frequent dosing regimen for <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a> (three to four times daily) has been recommended during pregnancy to prevent withdrawal and sustain adherence, due to its altered pharmacokinetics during gestation [<a href="#rid18">18,19</a>]. In addition to baseline MOUD, we use the typical analgesic regimens used for patients without opioid tolerance (ie, neuraxial labor analgesia, multimodal post-cesarean delivery analgesia including neuraxial opioids). Options for managing breakthrough pain include supplemental doses of MOUD if the baseline dose was not maximized, use of other opioids, or for cesarean delivery, peripheral nerve blocks. (See <a class="local">'Post-cesarean delivery analgesia'</a> below.)</p><p>The decision to continue or modify the dose of <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a> before surgery or an acute pain episode is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/121628.html" rel="external">"Management of acute pain in adults with opioid use disorder", section on 'Whether to continue buprenorphine during pain management'</a>.)</p><p>Patients with untreated OUD are at high risk for withdrawal when hospitalized without access to opioids they regularly consume outside of the hospital. For patients who use illicit opioids, baseline opioid dose may be impossible to determine. In this setting, patients admitted for delivery with untreated OUD who are willing to start MOUD can be initiated on <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> or <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a> to minimize withdrawal, with additional rescue opioid treatment for analgesia as needed. Patients who are unwilling to start MOUD and who receive standard anesthesia and analgesia for labor and delivery should be closely monitored for withdrawal.  </p><p class="headingAnchor" id="H3675984689"><span class="h2">Use multimodal analgesia</span><span class="headingEndMark"> — </span>Multimodal analgesia should be used for all patients, including neuraxial analgesia, nonpharmacologic strategies, regional anesthesia techniques as applicable, nonopioid analgesics, and opioids when necessary. (See <a class="local">'Labor analgesia'</a> below and <a class="local">'Postpartum analgesia'</a> below.)</p><p class="headingAnchor" id="H2445648019"><span class="h2">Avoid using opioid antagonists</span><span class="headingEndMark"> — </span>Opioid antagonists or agonist-antagonists can precipitate acute withdrawal and should be avoided [<a href="#rid13">13,20</a>]. Examples of these drugs are <a class="drug drug_general" data-topicid="9676" href="/z/d/drug information/9676.html" rel="external">nalbuphine</a> hydrochloride, <a class="drug drug_general" data-topicid="9753" href="/z/d/drug information/9753.html" rel="external">pentazocine</a>, <a class="drug drug_general" data-topicid="9179" href="/z/d/drug information/9179.html" rel="external">butorphanol</a> tartrate, and <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a>. If any of these drugs are given inadvertently, withdrawal can be reversed with any full opioid agonist. Obstetric and nursing teams who may be accustomed to administering nalbuphine or butorphanol to obstetric patients to treat labor pain or itching should be cautioned against its use in this population, given the risk of acute withdrawal [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H700908052"><span class="h2">Monitor for sedation, respiratory depression, and withdrawal</span><span class="headingEndMark"> — </span>Patients who chronically use opioids may be at increased risk of respiratory depression when additional opioids or sedatives are administered. These patients should be monitored similarly to high-risk patients receiving neuraxial <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a> or <a class="drug drug_general" data-topicid="8538" href="/z/d/drug information/8538.html" rel="external">hydromorphone</a>  (<a class="graphic graphic_algorithm graphicRef126139" href="/z/d/graphic/126139.html" rel="external">algorithm 1</a>).</p><p>Increased risk of adverse peripartum outcomes in patients with opioid dependence or abuse were reported in a large database study that used the US Nationwide Inpatient Sample [<a href="#rid21">21</a>]. Opioid dependence was associated with increased odds of maternal death (0.03 versus 0.006 percent) and cardiac arrest (0.04 versus 0.01 percent) during hospitalization for delivery compared with patients without opioid abuse or dependence, though the absolute risks of these events were very low. Whether these outcomes were the result of respiratory depression, withdrawal, or other confounding events or patient characteristics could not be determined.</p><p>All providers must recognize symptoms of opioid withdrawal, which may occur during admission for labor and delivery if patients do not reveal a history of OUD, if they are under treated during hospitalization, or if they inadvertently receive mixed agonist-antagonist or antagonist therapy that precipitates withdrawal  (<a class="graphic graphic_table graphicRef81045" href="/z/d/graphic/81045.html" rel="external">table 3</a>). Some institutions use a tool for standardized monitoring for withdrawal (eg, the Clinical Opioid Withdrawal Scale  (<a class="graphic graphic_table graphicRef106994" href="/z/d/graphic/106994.html" rel="external">table 4</a>)).</p><p class="headingAnchor" id="H3744659374"><span class="h1">LABOR ANALGESIA</span><span class="headingEndMark"> — </span>We suggest the use of neuraxial analgesia for parturients with OUD or chronic opioid use to provide optimal analgesia and minimal side effects for the parturient and fetus. For patients with contraindications to neuraxial analgesia or for those who refuse it, patient-controlled analgesia (PCA) may be offered  (<a class="graphic graphic_table graphicRef132055" href="/z/d/graphic/132055.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/101803.html" rel="external">"Neuraxial analgesia for labor and delivery (including instrumental delivery)"</a> and  <a class="medical medical_review" href="/z/d/html/4468.html" rel="external">"Pharmacologic management of pain during labor and delivery", section on 'Patient controlled analgesia (PCA)'</a>.)</p><p>A priority for managing patients with OUD or on chronic opioid therapy is to minimize the need for systemic opioids over and above their baseline. Thus, we counsel patients on the benefits of neuraxial analgesia, both to optimize pain relief and to avoid systemic opioids.</p><p class="headingAnchor" id="H861174832"><span class="h2">Neuraxial analgesia</span><span class="headingEndMark"> — </span>We initiate labor epidurals for patients with chronic opioid use or OUD at the time of patient request, dosed according to standard institutional protocol, with administration of additional boluses or increased infusion rate as needed. (See  <a class="medical medical_review" href="/z/d/html/101803.html" rel="external">"Neuraxial analgesia for labor and delivery (including instrumental delivery)"</a>.)</p><p>For patients taking <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> or <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a> for OUD, existing data do not suggest the need to alter doses of epidural or spinal opioids for vaginal or cesarean delivery. Patients on MOUD have pain and analgesic requirements during labor similar to patients who were not on MOUD [<a href="#rid13">13,14</a>].</p><p class="headingAnchor" id="H2733803518"><span class="h2">Systemic analgesics</span><span class="headingEndMark"> — </span>For patients with contraindications to neuraxial analgesia or who refuse it, baseline opioid dose can be increased, or other systemic opioids or <a class="drug drug_general" data-topicid="10086" href="/z/d/drug information/10086.html" rel="external">nitrous oxide</a> can be administered. For patients who receive systemic opioids, opioids with high potency or a high mu-opioid receptor affinity such as <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a>, <a class="drug drug_general" data-topicid="8538" href="/z/d/drug information/8538.html" rel="external">hydromorphone</a>, or <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a> may be preferable, particularly for patients on <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a>. The risks of return to substance abuse should be considered in determining whether to administer systemic opioids, given that such relapse can be associated both with exposure to systemic opioids or with poor pain control that ensues from avoidance of opioids [<a href="#rid22">22</a>]. (See  <a class="medical medical_review" href="/z/d/html/4468.html" rel="external">"Pharmacologic management of pain during labor and delivery", section on 'Systemic analgesics'</a>.) </p><p class="bulletIndent1"><span class="glyph">●</span>Importantly, avoid using opioid agonist/antagonist drugs for labor analgesia. (See <a class="local">'Avoid using opioid antagonists'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10086" href="/z/d/drug information/10086.html" rel="external">Nitrous oxide</a> should be used with caution in patients who take opioids because of added risk of respiratory depression. (See  <a class="medical medical_review" href="/z/d/html/4468.html" rel="external">"Pharmacologic management of pain during labor and delivery", section on 'Nitrous oxide'</a>.)</p><p></p><p class="headingAnchor" id="H238910562"><span class="h1">ANESTHESIA FOR CESAREAN DELIVERY</span><span class="headingEndMark"> — </span>We do not typically modify our usual choice of anesthetic technique for cesarean delivery for patients with OUD or who chronically use opioids. We use neuraxial anesthesia with multimodal analgesia based on the doses of long-acting hydrophilic neuraxial opioids we use for patients who do not chronically use opioids. We choose the type of neuraxial anesthesia (ie, spinal, combined spinal-epidural, epidural) based on patient and obstetric factors. We may rarely offer epidural catheter placement specifically for postoperative analgesia for patients who have high levels of anxiety regarding pain control, who request maximal opioid avoidance, or who are taking very high doses of opioids. Doses of neuraxial opioids and options for post-cesarean analgesia are discussed below  (<a class="graphic graphic_table graphicRef132055" href="/z/d/graphic/132055.html" rel="external">table 1</a>). (See <a class="local">'Post-cesarean delivery analgesia'</a> below.)</p><p>Patients with OUD or chronic opioid use may experience increased anxiety during neuraxial anesthesia for cesarean delivery compared with other patients. In our experience, these needs can usually be met with nonpharmacologic support, and increased need for anxiolytic medication has not been reported in the literature. We occasionally administer <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> (eg, 10 to 30 mg IV with <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">midazolam</a> 1 to 2 mg IV pretreatment) as an adjunctive sedating medication in patients with OUD, if the patient has an adequate block but poor coping mechanisms during cesarean delivery. </p><p class="headingAnchor" id="H2334408447"><span class="h1">POSTPARTUM ANALGESIA</span><span class="headingEndMark"> — </span>The postpartum period is a critical time for patients with OUD or chronic opioid use as postpartum pain may be more difficult to control. Severe acute postpartum pain may be associated with increased risk of persistent pain and depression [<a href="#rid7">7</a>]. Maintenance doses of medication for opioid use disorder (MOUD) should be continued throughout the postpartum period. </p><p class="headingAnchor" id="H2296864627"><span class="h2">Analgesia after vaginal delivery</span><span class="headingEndMark"> — </span>Patients who are opioid tolerant may require enhanced analgesia after vaginal delivery, over and above routine care. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Routine postpartum analgesia –</strong> We administer regularly scheduled <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> and nonsteroidal antiinflammatory drugs (NSAIDs) starting after delivery in addition to standard postpartum pain control measures, and add opioids only as necessary. (See  <a class="medical medical_review" href="/z/d/html/6711.html" rel="external">"Overview of the postpartum period: Normal physiology and routine maternal care", section on 'Vaginal birth'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with perineal tears –</strong> We offer long-acting neuraxial opioid (eg, <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a> or <a class="drug drug_general" data-topicid="8538" href="/z/d/drug information/8538.html" rel="external">hydromorphone</a>) to patients who have third or fourth degree perineal tears with neuraxial anesthesia. We use doses similar to those that are used for post-cesarean delivery analgesia. (See <a class="local">'Patients who have neuraxial anesthesia'</a> below.)</p><p></p><p class="headingAnchor" id="H1847596708"><span class="h2">Post-cesarean delivery analgesia</span><span class="headingEndMark"> — </span>The optimal strategy for post-cesarean delivery analgesia has not been determined, and practice varies. Our approach is described here and appears in a table  (<a class="graphic graphic_table graphicRef132055" href="/z/d/graphic/132055.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H3871469727"><span class="h3">Patients who have neuraxial anesthesia</span><span class="headingEndMark"> — </span>For these patients, we use a multimodal postoperative analgesic strategy similar to patients without OUD or chronic opioid use, based on hydrophilic neuraxial opioids and regularly scheduled nonopioid analgesics. (See  <a class="medical medical_review" href="/z/d/html/121755.html" rel="external">"Post-cesarean delivery analgesia", section on 'Our approach'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neuraxial hydrophilic opioids –</strong> We administer the same doses of neuraxial opioids for patients who are opioid tolerant and for those who are opioid naïve (preservative free <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a> 100 mcg intrathecal or 2 mg epidural), since not all opioid tolerant patients require increased postoperative analgesia [<a href="#rid13">13-15</a>], and higher opioid doses are associated with increased side effects, particularly respiratory depression and pruritus. (See  <a class="medical medical_review" href="/z/d/html/121755.html" rel="external">"Post-cesarean delivery analgesia", section on 'Side effects and complications'</a>.)  </p><p></p><p class="bulletIndent1">There are no randomized trials on post-cesarean analgesia in this patient population, and the optimal dose of neuraxial opioids for opioid tolerant patients is unknown. Practice varies, and some authors suggest increasing the dose of neuraxial opioids above that which would be used for non-opioid tolerant patients [<a href="#rid23">23</a>]. </p><p></p><p class="bulletIndent1">Whether <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a> reduces the efficacy of neuraxial opioids is unknown, and no study has demonstrated this effect. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neuraxial adjuncts – </strong>Neuraxial <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">clonidine</a> may enhance analgesia after cesarean delivery, but is associated with increased intraoperative hypotension and sedation. Routine use is not warranted based on current data, though it may be appropriate in some patients who are expected to have difficulty with pain control, after consideration of possible side effects. (See  <a class="medical medical_review" href="/z/d/html/121755.html" rel="external">"Post-cesarean delivery analgesia", section on 'Neuraxial adjuvants'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">Ketamine</a><strong> –</strong> We rarely administer ketamine as part of multimodal analgesia for cesarean delivery. We consider intraoperative ketamine (10 to 30 mg IV or an infusion at 3 to 5 mcg/kg/minute) for patients with a history of poor postoperative analgesia after prior surgery or for patients who are very motivated to maximally avoid opioids.</p><p></p><p class="headingAnchor" id="H2409727084"><span class="h3">Patients who have general anesthesia</span><span class="headingEndMark"> — </span>For these patients we administer regularly scheduled nonopioid analgesics (ie, <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> and NSAIDs), offer bilateral transversus abdominis plane (TAP) or quadratus lumborum (QL) blocks (single injection or continuous), and start intravenous patient-controlled analgesia (PCA) with opioids, transitioned to oral opioids by postoperative day 1. When possible, we may place an epidural catheter postoperatively for continuous epidural analgesia, though the risks of limited postoperative mobility and subsequent thromboembolic events should be considered. </p><p>We often use long-acting <a class="drug drug_general" data-topicid="17057" href="/z/d/drug information/17057.html" rel="external">liposomal bupivacaine</a> for TAP blocks when needed for severe breakthrough pain, but the possibility that this group of patients, many of whom may suffer from opioid-induced hyperalgesia, may require further local anesthetic administration should be considered before administering liposomal bupivacaine. Additional local anesthetics should not be administered for 96 hours after liposomal bupivacaine, to avoid local anesthetic systemic toxicity. Use of liposomal bupivacaine in general and for TAP block for cesarean delivery is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/14929.html" rel="external">"Clinical use of local anesthetics in anesthesia", section on 'Liposomal bupivacaine'</a> and  <a class="medical medical_review" href="/z/d/html/121755.html" rel="external">"Post-cesarean delivery analgesia", section on 'Peripheral nerve blocks'</a>.)</p><p>Local anesthetic wound infiltration is another option for post-cesarean delivery analgesia. The limited literature on wound infiltration suggests that benefits are modest, and likely nonexistent for patients who receive neuraxial opioids (see  <a class="medical medical_review" href="/z/d/html/121755.html" rel="external">"Post-cesarean delivery analgesia", section on 'Wound infiltration'</a>). We do not use wound infiltration or wound catheters in patients who receive neuraxial opioids or peripheral nerve blocks for postoperative analgesia. </p><p class="headingAnchor" id="H3046323795"><span class="h3">Severe or ongoing pain</span><span class="headingEndMark"> — </span>For severe or ongoing pain after the analgesic options described above, options include IV opioids (by intermittent bolus or PCA), rescue epidural analgesia, rescue bilateral TAP or QL blocks, and/or oral <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> for select patients, though there is scant evidence of efficacy of gabapentin. For patients who receive gabapentin, enhanced monitoring for sedation and respiration may be required for the mother and for breastfed neonates. Use of gabapentin for post-cesarean delivery analgesia is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/121755.html" rel="external">"Post-cesarean delivery analgesia", section on 'Adjuvant analgesics'</a>.)</p><p class="headingAnchor" id="H292498027"><span class="h1">PATIENTS WITH PRIOR OUD NOW ABSTINENT</span><span class="headingEndMark"> — </span>Medication for opioid use disorder(MOUD) is preferred for most patients, though some patients choose psychosocial treatment alone. Patients who are abstinent in recovery from OUD may be more vulnerable to relapse and have heightened anxiety about the medical setting, the pain of delivery, and pain relief that may be required in the peripartum period  (<a class="graphic graphic_table graphicRef132055" href="/z/d/graphic/132055.html" rel="external">table 1</a>). </p><p class="bulletIndent1"><span class="glyph">●</span>There are no data to suggest that the risk of relapse is increased if neuraxial opioids are administered. Therefore, neuraxial opioids should be used for labor analgesia, for analgesia after repair of third- or fourth-degree laceration, and for post-cesarean delivery analgesia, to maximize pain relief and minimize the need for systemic opioids. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Even patients who are currently abstinent may be opioid tolerant and may require higher doses of opioids. However, patients who have been abstinent for years likely have no increased opioid tolerance over opioid-naïve patients. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10086" href="/z/d/drug information/10086.html" rel="external">Nitrous oxide</a> can be offered as a nonopioid labor analgesic.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For postpartum analgesia, we administer regularly scheduled <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> and nonsteroidal antiinflammatory drugs (NSAIDs), in addition to routine care measures. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients who desire maximal opioid avoidance after cesarean delivery, we may offer a combined spinal epidural technique and leave the epidural catheter in place to provide postoperative continuous epidural analgesia in addition to regularly scheduled nonopioid analgesics. Additional options include peripheral nerve blocks and/or local anesthetic wound infiltration and perioperative <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a>. (See  <a class="medical medical_review" href="/z/d/html/121755.html" rel="external">"Post-cesarean delivery analgesia"</a>.)</p><p></p><p class="headingAnchor" id="H2816590353"><span class="h1">PATIENTS TAKING NALTREXONE</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9679" href="/z/d/drug information/9679.html" rel="external">Naltrexone</a> is a mu, kappa, and delta antagonist that may be used for treatment of OUD as for patients who choose to completely detoxify. If naltrexone is maintained until delivery, opioids are not likely to be effective for intrapartum and postpartum pain control. Naltrexone may over time increase the density of opioid receptors, such that the risk of side effects (eg, respiratory depression) may be increased if high doses of opioids are used (ie, the opioid antagonism is overcome), or if naltrexone is discontinued. </p><p>The efficacy of opioids is unpredictable, depending on the timing since the last dose of oral or intramuscular <a class="drug drug_general" data-topicid="9679" href="/z/d/drug information/9679.html" rel="external">naltrexone</a>. If naltrexone was not held for 48 to 72 hours or 30 days after an oral or intramuscular dose, respectively (or patients with a naltrexone implant in place), opioids will probably be ineffective. If naltrexone has been held for more than 48 to 72 hours after an oral dose or 30 days after an intramuscular dose, the patient may be more sensitive to opioids, and may be at risk for respiratory depression.</p><p>The literature on delivery in patients who are taking <a class="drug drug_general" data-topicid="9679" href="/z/d/drug information/9679.html" rel="external">naltrexone</a> is limited to small case series, with few details on peripartum pain management [<a href="#rid24">24,25</a>]. Starting naltrexone during gestation is typically avoided due to the need for detoxification and associated concerns. (See  <a class="medical medical_review" href="/z/d/html/4790.html" rel="external">"Opioid use disorder: Overview of treatment during pregnancy", section on 'Other pharmacotherapy'</a>.) </p><p>For patients who are taking <a class="drug drug_general" data-topicid="9679" href="/z/d/drug information/9679.html" rel="external">naltrexone</a> at the time of delivery, the following general approach is reasonable  (<a class="graphic graphic_table graphicRef132055" href="/z/d/graphic/132055.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Coordinate management closely with an addiction medicine specialist and the obstetric team.</p><p class="bulletIndent1"><span class="glyph">●</span>Avoid systemic and neuraxial opioids.</p><p class="bulletIndent1"><span class="glyph">●</span>Use regional anesthesia techniques with only local anesthetics for labor analgesia and post-cesarean delivery analgesia (eg, combined spinal-epidural, continuous epidural, transversus abdominis plane [TAP] or quadratus lumborum [QL] block, wound infiltration).</p><p class="bulletIndent1"><span class="glyph">●</span>If neuraxial analgesia is not possible for labor analgesia, offer <a class="drug drug_general" data-topicid="10086" href="/z/d/drug information/10086.html" rel="external">nitrous oxide</a>.</p><p class="bulletIndent1"><span class="glyph">●</span>For postpartum analgesia, administer regularly scheduled nonopioid analgesics in addition to routine care.</p><p></p><p>Management of acute pain in patients taking <a class="drug drug_general" data-topicid="9679" href="/z/d/drug information/9679.html" rel="external">naltrexone</a> is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/121628.html" rel="external">"Management of acute pain in adults with opioid use disorder", section on 'Patients taking naltrexone'</a>.)</p><p class="headingAnchor" id="H1451594293"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/131710.html" rel="external">"Society guideline links: Obstetric anesthesia"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/118165.html" rel="external">"Society guideline links: Substance misuse in pregnancy"</a>.) </p><p class="headingAnchor" id="H236369829"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preanesthesia consultation </strong>– Important issues that should be discussed during antenatal consultation include the details of current opioid therapy, concomitant medications including illicit substances, nicotine use, and concurrent psychiatric issues. Patient concerns regarding pain management and peripartum opioid use should be explored. (See <a class="local">'Antenatal anesthesia consultation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General principles of peripartum management </strong>– Important principles for peripartum management include the following (see <a class="local">'General principles'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Continue baseline opioid to avoid withdrawal</p><p class="bulletIndent2"><span class="glyph">•</span>Use multimodal opioid-sparing analgesia for labor, delivery, and postpartum pain</p><p class="bulletIndent2"><span class="glyph">•</span>Avoid administering agonist-antagonist medications (eg, <a class="drug drug_general" data-topicid="9676" href="/z/d/drug information/9676.html" rel="external">nalbuphine</a>, <a class="drug drug_general" data-topicid="9753" href="/z/d/drug information/9753.html" rel="external">pentazocine</a>, <a class="drug drug_general" data-topicid="9179" href="/z/d/drug information/9179.html" rel="external">butorphanol</a>) to avoid precipitating withdrawal</p><p class="bulletIndent2"><span class="glyph">•</span>Monitor for sedation, respiratory depression, and withdrawal</p><p></p><p class="bulletIndent1">Our strategy for peripartum management is shown in a table  (<a class="graphic graphic_table graphicRef132055" href="/z/d/graphic/132055.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Labor analgesia </strong>– We initiate neuraxial labor analgesia upon patient request, using the usual doses of local anesthetics and opioids. For patients with contraindications or who refuse neuraxial analgesia, patient-controlled analgesia (PCA) may be offered. <a class="drug drug_general" data-topicid="10086" href="/z/d/drug information/10086.html" rel="external">Nitrous oxide</a> should be used with caution because of added risk of respiratory depression  (<a class="graphic graphic_table graphicRef132055" href="/z/d/graphic/132055.html" rel="external">table 1</a>). (See <a class="local">'Labor analgesia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anesthesia for cesarean delivery </strong>–<strong> </strong>We do not modify the anesthetic for cesarean delivery for patients with chronic opioid use or opioid use disorder (OUD). We use neuraxial anesthesia, with multimodal analgesia based on usual doses of long-acting neuraxial opioids  (<a class="graphic graphic_table graphicRef132055" href="/z/d/graphic/132055.html" rel="external">table 1</a>). (See <a class="local">'Anesthesia for cesarean delivery'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postpartum analgesia </strong>–<strong> </strong>For all patients<strong> </strong>we administer regularly scheduled <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> and nonsteroidal antiinflammatory drugs (NSAIDs), along with routine postpartum care  (<a class="graphic graphic_table graphicRef132055" href="/z/d/graphic/132055.html" rel="external">table 1</a>). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>After vaginal delivery – For patients who have third or fourth degree vaginal tears, we offer long-acting neuraxial opioids at the same doses we use for cesarean delivery. (See <a class="local">'Analgesia after vaginal delivery'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Post cesarean delivery analgesia </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients who have neuraxial anesthesia, we administer hydrophilic neuraxial opioids at routine doses (ie, preservative-free <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a> 100 mcg intrathecal or 2 mg epidural), since not all opioid tolerant patients require increased postoperative analgesia, and side effects are dose dependent. (See <a class="local">'Patients who have neuraxial anesthesia'</a> above.) </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients who have general anesthesia, we offer bilateral transversus abdominis plane blocks (TAP) or quadratus lumborum (QL) blocks and start IV PCA, transitioned to oral opioids by the first postoperative day. We may place an epidural catheter postoperatively for continuous analgesia. (See <a class="local">'Patients who have general anesthesia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with prior OUD, now abstinent</strong>  (<a class="graphic graphic_table graphicRef132055" href="/z/d/graphic/132055.html" rel="external">table 1</a>)<strong> </strong>(see <a class="local">'Patients with prior OUD now abstinent'</a> above) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We administer neuraxial opioids for labor analgesia, for analgesia after repair of third- or fourth-degree laceration, and for post-cesarean delivery analgesia, to maximize pain relief and minimize the need for systemic opioids. There are no data to suggest that the risk of relapse is increased if neuraxial opioids are administered. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10086" href="/z/d/drug information/10086.html" rel="external">Nitrous oxide</a> is an option for labor analgesia for patients who prefer to delay or avoid labor epidural analgesia.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who desire maximal opioid avoidance after cesarean delivery, we may place a combined spinal-epidural for anesthesia and leave the epidural catheter in place for postoperative analgesia. Other options include TAP or QL blocks, local anesthetic wound infiltration or catheters, and/or oral <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a>. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients taking </strong><a class="drug drug_general" data-topicid="9679" href="/z/d/drug information/9679.html" rel="external">naltrexone</a><strong> </strong>– For patients taking naltrexone, we avoid systemic and neuraxial opioids and use neuraxial techniques with local anesthetics only. The efficacy of opioids is unpredictable depending on the timing of the last dose of naltrexone. If naltrexone still has a pharmacologic effect, opioids will probably be ineffective. If the last oral dose was &gt;48 to 72 hours ago, the patient may be more sensitive to opioids and at risk for respiratory depression  (<a class="graphic graphic_table graphicRef132055" href="/z/d/graphic/132055.html" rel="external">table 1</a>). (See <a class="local">'Patients taking naltrexone'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Committee Opinion No. 711: Opioid Use and Opioid Use Disorder in Pregnancy. Obstet Gynecol 2017; 130:e81.</a></li><li><a class="nounderline abstract_t">Soens MA, He J, Bateman BT. Anesthesia considerations and post-operative pain management in pregnant women with chronic opioid use. Semin Perinatol 2019; 43:149.</a></li><li><a class="nounderline abstract_t">Krans EE, Cochran G, Bogen DL. Caring for Opioid-dependent Pregnant Women: Prenatal and Postpartum Care Considerations. Clin Obstet Gynecol 2015; 58:370.</a></li><li><a class="nounderline abstract_t">Höflich AS, Langer M, Jagsch R, et al. Peripartum pain management in opioid dependent women. Eur J Pain 2012; 16:574.</a></li><li><a class="nounderline abstract_t">Ip HY, Abrishami A, Peng PW, et al. Predictors of postoperative pain and analgesic consumption: a qualitative systematic review. Anesthesiology 2009; 111:657.</a></li><li><a class="nounderline abstract_t">Jin J, Peng L, Chen Q, et al. Prevalence and risk factors for chronic pain following cesarean section: a prospective study. BMC Anesthesiol 2016; 16:99.</a></li><li><a class="nounderline abstract_t">Eisenach JC, Pan PH, Smiley R, et al. Severity of acute pain after childbirth, but not type of delivery, predicts persistent pain and postpartum depression. Pain 2008; 140:87.</a></li><li><a class="nounderline abstract_t">Krans EE, Campopiano M, Cleveland LM, et al. National Partnership for Maternal Safety: Consensus Bundle on Obstetric Care for Women With Opioid Use Disorder. Obstet Gynecol 2019; 134:365.</a></li><li><a class="nounderline abstract_t">Mittal L, Suzuki J. Feasibility of collaborative care treatment of opioid use disorders with buprenorphine during pregnancy. Subst Abus 2017; 38:261.</a></li><li><a class="nounderline abstract_t">Leighton BL, Crock LW. Case Series of Successful Postoperative Pain Management in Buprenorphine Maintenance Therapy Patients. Anesth Analg 2017; 125:1779.</a></li><li><a class="nounderline abstract_t">Jones HE, O'Grady K, Dahne J, et al. Management of acute postpartum pain in patients maintained on methadone or buprenorphine during pregnancy. Am J Drug Alcohol Abuse 2009; 35:151.</a></li><li><a class="nounderline abstract_t">Tith S, Bining G, Bollag L. Management of eight labor and delivery patients dependent on buprenorphine (Subutex™): A retrospective chart review. F1000Res 2018; 7:7.</a></li><li><a class="nounderline abstract_t">Meyer M, Wagner K, Benvenuto A, et al. Intrapartum and postpartum analgesia for women maintained on methadone during pregnancy. Obstet Gynecol 2007; 110:261.</a></li><li><a class="nounderline abstract_t">Meyer M, Paranya G, Keefer Norris A, Howard D. Intrapartum and postpartum analgesia for women maintained on buprenorphine during pregnancy. Eur J Pain 2010; 14:939.</a></li><li><a class="nounderline abstract_t">Jones HE, Johnson RE, Milio L. Post-cesarean pain management of patients maintained on methadone or buprenorphine. Am J Addict 2006; 15:258.</a></li><li><a class="nounderline abstract_t">Cassidy B, Cyna AM. Challenges that opioid-dependent women present to the obstetric anaesthetist. Anaesth Intensive Care 2004; 32:494.</a></li><li><a class="nounderline abstract_t">Cobb J, Craig W, Richard J, et al. A Retrospective Study of Acute Postoperative Pain After Cesarean Delivery in Patients With Opioid Use Disorder Treated With Opioid Agonist Pharmacotherapy. J Addict Med 2022; 16:549.</a></li><li><a class="nounderline abstract_t">Caritis SN, Bastian JR, Zhang H, et al. An evidence-based recommendation to increase the dosing frequency of buprenorphine during pregnancy. Am J Obstet Gynecol 2017; 217:459.e1.</a></li><li><a class="nounderline abstract_t">Elkader A, Sproule B. Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. Clin Pharmacokinet 2005; 44:661.</a></li><li><a class="nounderline abstract_t">Mitra S, Sinatra RS. Perioperative management of acute pain in the opioid-dependent patient. Anesthesiology 2004; 101:212.</a></li><li><a class="nounderline abstract_t">Maeda A, Bateman BT, Clancy CR, et al. Opioid abuse and dependence during pregnancy: temporal trends and obstetrical outcomes. Anesthesiology 2014; 121:1158.</a></li><li><a class="nounderline abstract_t">Lim G, Soens M, Wanaselja A, et al. A Systematic Scoping Review of Peridelivery Pain Management for Pregnant People With Opioid Use Disorder: From the Society for Obstetric Anesthesia and Perinatology and Society for Maternal Fetal Medicine. Anesth Analg 2022; 135:912.</a></li><li><a class="nounderline abstract_t">Landau R. Post-cesarean delivery pain. Management of the opioid-dependent patient before, during and after cesarean delivery. Int J Obstet Anesth 2019; 39:105.</a></li><li><a class="nounderline abstract_t">Towers CV, Katz E, Weitz B, Visconti K. Use of naltrexone in treating opioid use disorder in pregnancy. Am J Obstet Gynecol 2020; 222:83.e1.</a></li><li><a class="nounderline abstract_t">Wachman EM, Saia K, Miller M, et al. Naltrexone Treatment for Pregnant Women With Opioid Use Disorder Compared With Matched Buprenorphine Control Subjects. Clin Ther 2019; 41:1681.</a></li></ol></div><div id="topicVersionRevision">Topic 130304 Version 8.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28742676" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Committee Opinion No. 711: Opioid Use and Opioid Use Disorder in Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30791974" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Anesthesia considerations and post-operative pain management in pregnant women with chronic opioid use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25775440" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Caring for Opioid-dependent Pregnant Women: Prenatal and Postpartum Care Considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22396085" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Peripartum pain management in opioid dependent women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19672167" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Predictors of postoperative pain and analgesic consumption: a qualitative systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27756207" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Prevalence and risk factors for chronic pain following cesarean section: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18818022" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Severity of acute pain after childbirth, but not type of delivery, predicts persistent pain and postpartum depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31306323" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : National Partnership for Maternal Safety: Consensus Bundle on Obstetric Care for Women With Opioid Use Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26672650" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Feasibility of collaborative care treatment of opioid use disorders with buprenorphine during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29049122" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Case Series of Successful Postoperative Pain Management in Buprenorphine Maintenance Therapy Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19462298" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Management of acute postpartum pain in patients maintained on methadone or buprenorphine during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29527296" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Management of eight labor and delivery patients dependent on buprenorphine (Subutex™): A retrospective chart review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17666599" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Intrapartum and postpartum analgesia for women maintained on methadone during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20444630" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Intrapartum and postpartum analgesia for women maintained on buprenorphine during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16923675" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Post-cesarean pain management of patients maintained on methadone or buprenorphine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15675209" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Challenges that opioid-dependent women present to the obstetric anaesthetist.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35165223" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A Retrospective Study of Acute Postoperative Pain After Cesarean Delivery in Patients With Opioid Use Disorder Treated With Opioid Agonist Pharmacotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28669739" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : An evidence-based recommendation to increase the dosing frequency of buprenorphine during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15966752" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15220793" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Perioperative management of acute pain in the opioid-dependent patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25405293" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Opioid abuse and dependence during pregnancy: temporal trends and obstetrical outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A Systematic Scoping Review of Peridelivery Pain Management for Pregnant People With Opioid Use Disorder: From the Society for Obstetric Anesthesia and Perinatology and Society for Maternal Fetal Medicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31005380" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Post-cesarean delivery pain. Management of the opioid-dependent patient before, during and after cesarean delivery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31376396" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Use of naltrexone in treating opioid use disorder in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31358302" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Naltrexone Treatment for Pregnant Women With Opioid Use Disorder Compared With Matched Buprenorphine Control Subjects.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
